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The Polish Society of Colposcopy and Cervical Pathophysiology and the Polish Society of Gynecologists and Obstetricians 
provide comprehensive guidelines for colposcopy practice in secondary cervical cancer prevention in Poland. This part of 
the guidelines, developed by the clinical experts of the Working Group No. 1 (WG1), concerns the colposcopy protocols 
with the main aim of algorithmizing the procedure, together with all procedure-related processes. The detailed analysis of 
strong scientific evidence and an extensive literature review of current international colposcopic recommendations were 
carried out, with also a broad investigation of recently ongoing dynamic changes in national health systems. The attention 
to colposcopic limitations also occurring in Polish conditions was kept. The overriding goal was the recommended obliga-
tory minimal colposcopy approach introduction. To enhance the standard of colposcopy, adjustment of a precolposcopic 
assessment, a performance technique, types of used biopsies, as well as the procedure documentation was made. Elements 
of the risk-based stratification for the increased risk of developing cervical cancer was also included if it was applicable 
for that part of the guidelines. Comprehensive colposcopy guidelines are a step towards the ongoing era of a precision 
medicine in cervical cancer prevention in Poland.
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The limitations of a diagnostic value of colposcopies are 
widely known [2, 3], unfortunately they are far from expected. 
The sensitivity of colposcopies for detecting high-grade cervi-
cal squamous intraepithelial lesions, with subcategorization 
to cervical intraepithelial neoplasia grade 3 and greater [HSIL 
(CIN3+)], ranges from 50 to 65%, depending on the study [5–9]. 
The Consensus was based on a strong evidence with 
extensive review of current international colposcopic stand-
ards [1–5, 10–38] and on the Committee’s own experience. 
Significant limitations resulting from the insufficient avail-
ability of properly standardized research, especially in a Pol-
ish population, was also maintained.
Participation in the Consensus of pathologists and 
gynecological cytopathologists aimed at interdisciplinary 
analysis of all colposcopy-related processes and a diagnostic 
background, which is an important factor in the continuous 
pursuit of precision medicine.
The complexity of the colposcopy standardization in 
Poland is the coexistence of three CCS models: two financed 
from public funds, i.e. population-based (currently not con-
tinued) and opportunistic, and one outside the public sys-
tem based also on the opportunistic model [39].
The recommendations present current management that 
can be modified and changed in justified cases, after careful 
analysis of a given clinical situation, which in the future may 
constitute grounds for their modification and updating.
INTRODUCTION TO COMPREHENSIVE 
GUIDELINES FOR STANDARDS IN 
COLPOSCOPY 
“COLPOSCOPY 2020”
Colposcopic examination is one of diagnostic-therapeutic 
key points in the cervical cancer screening (CCS) [1, 2], regard-
less of the primary screening test used. Histopathological 
“gold standard” detection of high-grade squamous intraepi-
thelial lesions and cervical cancer is based on colposcopy [2].
The main purpose of these comprehensive colposcopy 
guidelines is the algorithmization of all processes accom-
panying this procedure, in achieving the highest possible 
sensitivity and specificity in Polish conditions [2–4]. In the 
recommended adjustment of the indications, implementa-
tion and colposcopy technique, a variety of currently used 
approaches in Poland, as well as varying levels of training 
and experience of colposcopists was considered.
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The specificities of Polish gynecological prophylaxis, 
including CCS, is an extraordinarily strong sector of a private 
medical service, rather unprecedented in other countries, 
paid by patients’ own resources without involvement of 
insurance companies. Many patients directly paying for 
health services expect to maximize their health interests, 
not population-based optimization or cost-effectiveness.
Secondary CCS in Poland in the opportunistic model 
financed from private funds is not sufficiently standardized 
and practically takes place beyond effective quality assess-
ment and quality control. The problem is compounded by 
the lack of comprehensive recommendations for CCS in our 
country for nearly 10 years [40], and its objective assessment 
due to the lack of comprehensive statistical data and screen-
ing results remaining outside of synthetic records [41–43].
The overriding goal of the Guidelines is to change the 
current state and introduce an original screening model 
that will allow to combine a standardized controlled op-
portunistic private CCS model with a population-based 
organized CCS model financed from public funds. 
It seems, in Polish conditions only a mixed screening 
model gives a chance to achieve the expected minimum 
70% screening coverage of women [44], which was indi-
rectly but clearly confirmed by the analysis of the Polish 
organized population model completed in 2017 [45]. 
Achieving at least minimal screening coverage will bring 
Poland closer to the fundamental objective of secondary 
CCS — reducing morbidity and mortality. The implemen-
tation of the above in association with primary prevention 
of cancer, opens the possibility of its epidemiological 
elimination [46].
Developing Polish colposcopic guidelines with the mini-
mal recommended colposcopy approach is a necessary step 
to achieve the objectives.
General aims of the Guidelines
The most important aims of Comprehensive Guidelines 
for Colposcopy Standards have been developed, based on 
the detailed analysis of strong scientific evidences, inter-
national guidelines of the highest-authority gynecological 
societies [2, 16, 37, 38] and on the own experience of the 
Committee members:
1. These guidelines address the colposcopic examination 
and cervical biopsy in secondary cervical cancer pre-
vention.
2. They were specifically developed for the Polish condi-
tions, with considering the characteristic features of 
current CCS models in Poland.
3. Guidelines have been developed as understandable and 
easy to unambiguous interpretation as possible way, 
with the attention to uncomplicated popularization and 
application for educational purposes.
4. Recommended colposcopy approaches enable their 
effective implementation to national conditions.
5. The main goal was to indicate the minimal practice 
colposcopy guidelines, with “a nothing below” principle. 
6. The optimal and the optional practice colposcopy guide-
lines were also introduced.
Basics of colposcopy in the interdisciplinary 
approach
Strategic for understanding the basics of colposcopic 
examination is to define the transformation zone (TZ) and 
the squamo-columnar junction (SCJ). To minimizing limi-
tations of colposcopy, the Committee points the need for 
extended definition of both terms. 
SCJ and TZ are basic dynamic landmarks of the trans-
formation process. Transformation zone is the site for the 
occurrence of over 90% of cervical precancers, according 
with the LAST 2012 Project and WHO/IARC 2014 named 
high-grade squamous intraepithelial lesions (HSIL), and of 
the cervical cancer [2, 3, 47, 48].
The SCJ is defined as the interface between the stratified 
squamous and the cylindrical epithelium, and its location 
in the cervix varies. SCJ is the result of a continuous remod-
eling process associated with uterine growth, cervical size 
changes, obstetric history, hormonal status, cervical treat-
ment [49–51], and with a vaginal microbiome as well [52]. 
The process of a migration of the primary SCJ from the 
initial endocervical to ectocervical position, often distant 
from the ostium of the external cervical canal, is a physi-
ological phenomenon of reproductive period.
A gradual replacement of cylindrical epithelium by the 
stratified squamous epithelium is determined by the meta-
plasia process, which is initiated in response to the acidic 
vaginal environment [47, 49, 50].
Metaplasia is an adaptive process usually occurring 
under the prolonged irritation or hormonal factors. It is 
replacing one type of mature cell with another [53, 54]. 
A characteristic feature of cervical metaplasia is its multifo-
cality and the ability to merge smaller areas into larger ones, 
which has a direct impact on the potential multifocality of 
precancerous lesions, what might be particularly challeng-
ing for colposcopists.
The process of cervical metaplasia begins with the reserve 
cells lying under cylindrical epithelium. Reserve cells prolifera-
tion passing through the phase of immature to mature metapla-
sia causes creates a new epithelial junction (new SCJ) with cylin-
drical epithelium. The area between the primary and new SCJ 
is called the transformation zone [47, 49, 50]. A special feature 
of reserve cells is their increased susceptibility to HPV infection, 
which is the fundamental factor in cancer transformation [3].
For the reasons above, documenting the visualization 
of a new SCJ is one of the most important quality indicators 
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in colposcopy, as well as a location of colposcopic findings 
in relation to TZ.
The understanding of TZ and the new SCJ is being aware 
about their possible multifocal appearance. Transformation 
zone in histopathological meaning is the area in which 
squamous metaplasia may appear. Reserve cells initialing 
that process may apply not only to glandular crypts, whose 
depth may reach up to 10 mm, but may reach up to the 
isthmus. Precancerous lesions located in these places might 
be undetected during colposcopy [48, 55–58].
In the opinion of the Committee’s Experts, awareness 
of the limitations of colposcopy, should result in the use of 
procedures reducing the diagnostic failure. This applies to 
endocervical sampling and to the standardization of random 
biopsy in cases of increased risk of HSIL (CIN2+) [59–61].
Committee members emphasize the possibility of de-
veloping two different histologic subtypes HSIL within TZ: 
classic HSIL, when it develops within mature metaplasia 
through the intermediate stage of LSIL; and thin HSIL. The 
latter develops within early metaplasia without the interme-
diate stage of LSIL, near the new SCJ. Thin HSIL has multi-
focal character and may coexist with classic HSIL, what all 
together may hinder a colposcopic examination [57, 62, 63].
Objectives of Working Group No. 1 on 
Colposcopic Protocols
WG1 recommends presented colposcopy protocols as 
a necessary component of diagnostic colposcopy approach. 
These might be complementary to other current nationwide 
guidelines or can be their integrated part.
The protocols are aimed at multi-level algorithmisation 
of the procedure in Polish conditions, focusing on indicating 
the minimal colposcopy approach.
Guidelines do not include diagnostic-therapeutic 
excisional procedures: electrical loop (LLETZ/LEEP) and 
surgical cold-knife. A multi-parameter risk stratification 
(based on additive analysis of precolposcopic screening 
tests results with colposcopic image) is recommended to 
treatment using excisional procedure without preceding 
biopsy [5].
Assessment of the strength of the 
recommendation
In assessing the level of evidence and strength of these 
guidelines, WG1 adopted the classification used in the “Euro-
pean recommendations for quality assessment in cc screen-
ing” [44] (Tab. 1 and 2). Due to the lack of relevant published 
research on the Polish population, level VI (expert opinions) 
of strength A (procedure strongly recommended), B (proce-
dure recommended) or C (procedure to be considered but of 
uncertain importance) was adopted for the all “Colposcopy 
2020” guidelines.
Major and minor screening abnormalities
WG1 recommends the major screening abnormalities 
terminology in assessment of the pre-colposcopic stage, 
defined as:
•	 screening test results implicating immediate colpos-
copy,
and following colposcopic lesions:
•	 minor colposcopic findings
•	 major colposcopic findings
•	 findings suspicious for invasion
•	 nonspecific findings (optional)
Which require the use of extended colposcopic protocol, 
specified in the guidelines as the optimal protocol. 
At the precolposcopic stage, minor colposcopic abnor-
malities include screening test results, which allow a con-
servative management in specific conditions, usually with 
follow-up after 12 months. At the colposcopic stage, minor 
colposcopic abnormalities include colposcopic findings 
sufficient for the use of the basic protocol.
More detailed definition of major and minor screening 
abnormalities of the precolposcopic stage remains outside 
the WG1 guidelines.
Table 1. Criteria used to assess the level of reliability of scientific 
evidence
Level  
of evidence: A criterion description
Level I
Consistent multiple randomized controlled trials 
(RCTs) of adequate sample size, or systematic 
reviews (SRs) of RCTs, taking into account 
heterogeneity
Level II One RCT of adequate sample size, or one or more RCTs with small sample size
Level III
Prospective cohort studies or SRs of cohort studies; 
for diagnostic accuracy questions, cross-sectional 
studies with verification by a reference standard
Level IV Retrospective case-control studies or SRs of case-control studies, trend analyses
Level V Case series; before/after studies without control group, cross- sectional surveys
Level VI Expert opinion





A. Intervention strongly recommended for all patients or targeted individuals
B. Intervention recommended
C. Intervention to be considered but with uncertainty about its impact
D. Intervention not recommended
E. Intervention strongly not recommended
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Excisional and ablative procedures
It was decided that protocols for excisional procedures 
— LLETZ/LEEP, “cold-knife” and ablative procedures (cryo- 
and laser ablation) should be developed after a comple-
tion of other WGs works, in particular the group working 
on indications for colposcopy, defining major and minor 
screening abnormalities.
Types of biopsy in HSIL (CIN2+) risk stratification
Colposcopy with targeted biopsy remains a diagnostic 
standard in HSIL (CIN2+) detection and the procedure of 
choice for making therapeutic decisions. Histopathological 
examination is the “gold standard” [3].
Indications, the number of taken biopsies and the tech-
nique of targeted biopsy differ significantly not only on 
recommendations [2, 16, 37, 38], but also between col-
poscopists [64].
WG1 recommends targeted biopsy when lesions diag-
nosed as follows are present:
•	 abnormal colposcopic findings,
•	 findings suspicious for invasion,
•	 suspicious metaplasia,
•	 other suspicious findings.
Whilst taking more, than one biopsy if needed [1, 3]. 
Many studies prove the limited efficacy of targeted bi-
opsy, e.g. the sensitivity for HSIL (CIN3+) varies from 50 to 
65%, depending on the study [5–9]. Targeted biopsy cannot 
be diagnostically effective enough, especially when precol-
poscopic major screening abnormalities were diagnosed 
and no colposcopic abnormalities are found.
Random biopsy is accepted as an optimal procedure to in-
crease the sensitivity of colposcopy for detecting HSIL (CIN2+), 
in cases when no colposcopic abnormalities were found.
Random biopsy is defined as a biopsy from each normal 
quadrant as 2, 4, 8 and 10 clock position at the new SCJ. 
If new SCJ is not visible a random biopsy is not recommended.
Random biopsy efficacy for HSIL (CIN2+) varies signifi-
cantly among different studies, with values ranging from 
3.8% to 37.4% [65, 66]. These discrepancies are the result 
of different definitions of abnormal colposcopic findings 
— a more liberal the definition of abnormality is used the 
less diagnostic random biopsy is [60].
WG1 recommends a colposcopic nomenclature in ac-
cordance with the 2011 IFCPC, translated into Polish with 
the IFCPC approval (in press).
Comparison of targeted and random biopsy with p16 im-
munohistochemical staining in cases of HSIL (CIN2 +), shows 
that lesions detected in random biopsy: 1) are more often 
limited to one cervical quadrant; 2) they are less often as-
sociated with cytological diagnoses of AGC, ASC-H, HSIL and 
cervical cancer; 3) are more frequent in women over 50 years; 
4) are less frequently associated with HPV 16 infection [67].
Independently, taking more biopsies increases colpo-
scopic diagnostic value, regardless of a colposcopists experi-
ence or the patient’s clinical status [59, 66].
For targeted and random biopsies, WG1 recommends 
microbiopsy tool with a cutting width of up to 2 mm, 
minimizing tissue traumatization and patient discomfort 
or pain. Taking more biopsies using microbiopsy instru-
ment does not reduce the patient’s acceptance of the 
procedure [61].
Colposcopic sensitivity for HSIL (CIN2) might be sub-
stantially increased, in specific clinical cases, by endocervi-
cal sampling with a detection rate is up to 16.7% (average 
5.5%) [59, 68].
Endocervical sampling can be taken by a traditional 
sharp curette or with endo-Cervex root by vigorous brush-
ing, or by using both methods. Diagnostic value of both 
method — ECC and ECB — is comparable [59, 68, 69]. En-
docervical brushing in most cases does not require dilata-
tion of the cervical canal, so it is a sparing procedure of 
choice. Endocervical sampling is not recommended during 
pregnancy [59].
Indications for ECC/ECB including HSIL (CIN2+) risk strati-
fication were listed in the basic protocol.
Endometrial sampling (minimally with aspiration bi-
opsy, e.g. using pipella device), in combination with colpos-
copy with ECC/ECB, is recommended in women of 35 years 
and older with AGC (all subcategories) or AIS in cytology. As 
well as in younger women with endometrial cancer risk (e.g. 
atypical hyperplasia/endometrial intraepithelial neoplasia 
in histology, abnormal uterine bleeding [59, 62], symptoms 
suggesting chronic lack of ovulation [70]). 
Recommended by WG1 a general approach for perform-
ing colposcopic examination covers:
•	 a colposcopic assessment of the cervix divided into 
quadrants with a clockwise manner (quadrant I — front 
left, II — rear left, III — rear right and IV — front right) 
to optimize the procedure.
•	 biopsy from all recommended areas (more than one 
biopsy if needed), with a rule of thumb — the worst 
lesion is usually located closest to new SCJ.
•	 in cases of precolposcopic major screening abnormali-
ties when no colposcopic abnormality was found a ran-
dom biopsy from each quadrant as 2, 4, 8 and 10 o’clock 
at new SCJ should be taken.
•	 endocervical sampling in all non-pregnant patients.
In HSIL (CIN2+) risk stratification, identification at least 
two major screening abnormalities of cytologic HSIL, posi-
tive HPV 16 and/or 18 infection and major colposcopic find-
ings is associated with higher risk of precancers than the 
occurrence only one major screening abnormality. 
Similarly, concurrent cytologic diagnosis less than HSIL, 
no HPV 16 and/or 18 infection, and no abnormal colpo-
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scopic findings is associated with a lower risk of precancer 
than the occurrence only one minor screening abnormality. 
Multi-parameter risk stratification increases a diagnostic value 
of secondary CCS, including analysis the results of colposcopic 
examination [5].
In the opinion of WG1, new imaging colposcopy tech-
nologies require clinical validation before they are intro-
duced into routine colposcopic practice [64, 71, 72].
Component procedures of colposcopy
According to these guidelines, a full colposcopy proce-
dure should consist of the following components:
1. Precolposcopic assessment.
2. Colposcopic examination with one of recommended 
colposcopy protocols. 
3. Documentation of colposcopic findings.
Precolposcopic assessment
WG1 recommends precolposcopic assessment with one 
of two recommended options:
•	 basic — obligatory minimum for precolposcopic as-
sessment.
•	 optimal — recommended precolposcopic assessment, 
optimal at the time of developing draft guidelines.
Assessment parameters for each option are listed in Table 3.
Colposcopy examination 
As the routine basic colposcopy technique, the following 
steps are recommended (in the order specified):
1. gross examination of vulva and vagina,
2. initial assessment of the cervix and upper vagina at dif-
ferent power magnifications*,
3. careful (without causing bleeding) application of saline 
with washing away the mucus, 
4. re-evaluation of the cervix and upper vagina at magnifi-
cation* and with green filter (necessary before applying 
acetic acid),
5. application of 3–5% acetic acid,
6. examine the cervix and upper vagina at different power 
colposcope magnifications* [73]:
a) after 1 minute routinely
b) after 3 minutes (optionally)
7. selection of lesions for biopsy,
8. colposcopic biopsy,
9. achieving and ensuring haemostasis.
*4 to 15 times magnified image recommended.
Photographic documentation at least of 3), 4) and 6 a) 
examination steps is recommended, if possible. WG1 points 
also that photo-documentation a post-biopsy step, can be 
a useful educational tool.
Due to the inclusion by the IFCPC the Lugol staining 
result (Schiller test) to non-specific colposcopic images, 
WG1 does not recommend Schiller test in the routine prac-
tice [74].
Colposcopy protocols — a systemic approach
WG1 recommends one of three levels of colposcopy 
protocols to use in routine colposcopy practice:
•	 BASIC — minimal colposcopy approach (obligatory).
•	 OPTIMAL — recommended colposcopy approach, 
optimal at the time of developing draft guidelines.
•	 OPTIONAL — approach accepted by Experts as having 
the highest diagnostic sensitivity in detecting histologic 
HSIL (CIN2+) at the time of developing draft guidelines.
The choice of the colposcopy protocol in screening mod-
els being founded by public resources is an autonomous 
decision of the founder.
The key principle for the physician participating in sec-
ondary CCS in the era of evidence-based precision medicine 
is a fundamental care for the patient’s health interest based 
on available experts’ guidelines and with the individualiza-
tion of a management.
Table 3. Options of precolposcopy assessment with recommended 
parameters
PRECOLPOSCOPY EVALUATION OPTIONS BASIC OPTIMAL
PARAMETER – –
Indications for colposcopy x x
Status/result of the last 
HPV/cytology/p16/Ki67 test x x
Status/result of the previous 
HPV/cytology/p16/Ki67 test x
Result of the previous colposcopy x
Excision/ablative procedures x
LMP — date or age x x
Pregnancy status x x
Obstetrical history x
HCT — type x
IUD — nonhormonal/hormonal x
Hormonal therapy — type x
Menopausal status/age of LMP x x
MHT — type x
Status post hysterectomy x x
Smoking x
HIV status x
HPV vaccination — name, number of doses x
Others — what? x
Informed consent of the patient x x
HPV — human papillomavirus; p16/Ki67 — immunocytochemical test 
p16/Ki67; HCT — hormonal contraceptive therapy; MHT — menopause 
hormone therapy; HIV — human immunodeficiency virus; IUD — intrauterine 
device; LMP — last menstrual period 
Basic pre-colposcopic evaluation in bold
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Dedicated obligatory biopsy types are recommended 
for all protocols, which does not exclude individualization 
of the decision to taking biopsy from other colposcopy 
suspected areas, which is depending on the clinical situ-
ation.
BASIC PROTOCOL — minimal colposcopy 
approach
According to the main goal of the guidelines a minimal 
colposcopy scope is recommended — the basic protocol 
should therefore be treated as an obligatory minimum col-
poscopy approach, which includes:
•	 ECC (minimum) and/or ECB (optional) in the case of:
  TZ3 (obligatory) and TZ2 (optional) (VI-A)
  positive status of HRHPV 16 and/or 18 (VI-B) 
  ASC-H+ (ASC-H and higher) cytologic results (VI-A)
  positive p16/Ki67 test result (VI-B) 
  abnormal colposcopic findings or suspicious for 
invasion (VI-A)
  all major screening abnormalities of precolposcopic 
stage when any colposcopic abnormalities were 
found (VI-B)
  considering the subsequent ablation treatment 
(cryo- or laser ablation) (VI-A) 
	[1, 3, 13, 16, 25, 29–33, 35, 44, 75, 76].
•	 Targeted biopsy (in particular, from lesions assessed 
as abnormal colposcopic findings, suspicious for inva-
sion, suspicious metaplasia and from other suspected 
areas) (VI-A)
Optional basic protocol is also acceptable (a variant 
without cases listed above in the basic protocol for ECC/ECB 
sampling): 
•	 always ECC (minimum) and/or ECB (optional) (VI-B)
•	 targeted biopsy (in particular, from lesions assessed as ab-
normal colposcopic findings, suspicious for invasion, suspi-
cious metaplasia and from other suspected areas) (VI-A)
OPTIMAL PROTOCOL — recommended 
colposcopy approach
Optimal protocol is recommended as the optimal bal-
ance between diagnostic value and the procedure extent at 
the time of developing draft guidelines. It includes:
•	 always ECC and/or ECB (VI-B)
•	 targeted biopsy (in particular, from lesions assessed as ab-
normal colposcopic findings, suspicious for invasion, suspi-
cious metaplasia and from other suspected areas) (VI-A)
•	 random biopsy for major screening abnormalities if no 
abnormal colposcopic findings were presented, if a new 
SCJ is visible (biopsies from each normal quadrant as 2, 
4, 8 and 10 clock position at new SCJ) (VI-B)
OPTIONAL PROTOCOL — accepted colposcopy 
approach
Optional protocol was approved for the use in Polish 
conditions as having potentially the highest diagnostic 
sensitivity in detecting histological HSIL, at the time of de-
veloping draft guidelines. It includes:
•	 ECC and/or ECB in each case (VI-B)
•	 targeted biopsy (in particular, from lesions assessed as ab-
normal colposcopic findings, suspicious for invasion, suspi-
cious metaplasia and from other suspected areas) (VI-A)
•	 random biopsy in each case of visualization of new SCJ 
from each normal quadrant as 2, 4, 8 and 10 clock posi-
tion at new SCJ) (VI-C).
Documentation of colposcopy
Documentation of colposcopic findings is recommend-
ed according to the IFCPC 2011. Colposcopic images should 
be saved in electronic medical records.
Description of the size and location of the lesion is rec-
ommended, and it covers as follows:
1. size of the lesion as number of cervical quadrants the 
lesion covers, 
2. size of the lesion as percentage of cervix involvement,
3. location by clock position,
4. location of the lesion in relation to the transformation 
zone (inside or outside).
A sample colposcopy report will be presented by the 
Committee after completing work of all WGs.
SUMMARY
Recognizing the need of national implementation of 
the consistent colposcopy practice standards with its sys-
temic algorithmization, the comprehensive guidelines for 
gynecologists, and other CCS specialists, were provided to 
increase a diagnostic value of colposcopy in current Pol-
ish conditions. Guidelines were based on strong evidence 
of the literature, extensive review of current international 
colposcopic standards and on the Committee’s own experi-
ence. A variety of currently used colposcopy approaches in 
Poland, levels of training and experience of colposcopists 
was considered during guidelines development as well. 
The use of one of three following colposcopic protocols 
is recommended in the colposcopy examination:
Table 4. Recommended levels of colposcopy approach, including 
minimal obligatory level for colposcopy practice. Detailed 
description of each approach in the main body of the guidelines
•	 BASIC — minimal colposcopy approach (obligatory)
•	 OPTIMAL — recommended colposcopy approach, optimal at the 
time of developing draft guidelines
•	 OPTIONAL — approach accepted by Experts as having the 
highest diagnostic sensitivity in detecting histologic HSIL (CIN2+) 
at the time of developing draft guidelines
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1. Basic protocol — presents the minimal colposcopy 
approach. It covers taking targeted biopsy (in particular, 
from lesions assessed as abnormal colposcopic find-
ings, suspicious for invasion, suspicious metaplasia 
and from other suspected areas) (VI-A) and endocervi-
cal sampling (ECC minimally and/or ECB optionally) 
in cases of: TZ3 (optional TZ2) (VI-A), positive HRHPV 
16 and/or 18 (VI-B), ASC-H+ cytologic results (VI-A), posi-
tive p16/Ki67 test (VI-B), abnormal colposcopic findings 
or suspicious of invasion (VI-A), no colposcopic abnor-
malities found in association with all major screening 
abnormalities of precolposcopic stage (VI-B), and in 
cases of planning ablation procedures (VI-A).
Performing ECC minimally and/or ECB optionally in each 
case (VI-B) without specific cases listed detailly in the 
basic protocol is also acceptable.
2. Optimal protocol — presents the recommended colpo-
scopic approach. It covers taking targeted biopsy (in par-
ticular, from lesions assessed as abnormal colposcopic 
findings, suspicious for invasion, suspicious metaplasia 
and from other suspected areas) (VI-A), taking random 
biopsy at the new SCJ (if visualized) from each normal 
quadrant as 2, 4, 8 and 10 clock position in the cases 
of major screening abnormalities when colposcopic 
abnormalities were not found (VI-B) and endocervical 
sampling in each case (ECC and/or ECB) (VI-B).
3. Optional protocol — presents the acceptable colpo-
scopic approach. It covers taking targeted biopsy (in par-
ticular, from lesions assessed as abnormal colposcopic 
findings, suspicious for invasion, suspicious metaplasia 
and from other suspected areas) (VI-A), taking random 
biopsy at the new SCJ in each case of its visualization 
from each normal quadrant as 2, 4, 8 and 10 clock posi-
tion (VI-C) and endocervical sampling in each case (ECC 
and/or ECB) (VI-B).
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